Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 3/2013

01-06-2013 | Review Article

Pharmacological Treatment of Acute Migraine in Adolescents and Children

Author: Çiçek Wöber-Bingöl

Published in: Pediatric Drugs | Issue 3/2013

Login to get access

Abstract

Migraine is a common disease in children and adolescents. The incidence of migraine has increased alarmingly in the general population during recent decades. Migraine causes considerable individual suffering and impaired quality of life. Therefore, appropriate management is essential. In this article, the treatment of acute migraine in children and adolescents will be reviewed. Only a few randomized controlled studies have been published and high placebo rates are a major problem for proving superiority of active drugs. Generally, acetaminophen (paracetamol) and ibuprofen are accepted as drugs of first choice, even though the evidence is poor for the former and limited for latter. Among 14 studies on triptans in adolescents, 9 showed some superiority over placebo with respect to pain relief and pain freedom, and among 6 studies in children, 5 suggest some superiority over placebo. Sumatriptan nasal spray and zolmitriptan nasal spray have been approved for adolescents in Europe; almotriptan has been approved for adolescents in the USA, as has rizatriptan for patients aged 6–17 years. A recent study demonstrated the efficacy of a fixed combination of sumatriptan and naproxen in adolescents with migraine. In conclusion, evidence for the pharmacological treatment of acute migraine in children is very poor and evidence for adolescents is better but still limited.
Literature
1.
Özge A, Termine C, Antonaci F, et al. Overview of diagnosis and management of paediatric headache. Part I: diagnosis. J Headache Pain. 2011;12(1):13–23.PubMedCrossRef
2.
Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52(12):1088–97.PubMedCrossRef
3.
Anttila P, Metsähonkala L, Sillanpää M. Long-term trends in the incidence of headache in Finnish schoolchildren. Pediatrics. 2006;117(6):e1197–201.PubMedCrossRef
4.
Wöber-Bingöl Ç, Wöber C, Karwautz A, et al. Diagnosis of headache in childhood and adolescence: a study in 437 patients. Cephalalgia. 1995;15(1):13–21.PubMedCrossRef
5.
Wöber-Bingöl Ç, Wöber C, Karwautz A, et al. Clinical features of migraine: a cross-sectional study in patients aged three to sixty-nine. Cephalalgia. 2004;24(1):12–7.PubMedCrossRef
6.
Wöber-Bingöl Ç, Martin IP. Managing headache in young people. In: Martelletti P, Steiner TJ, editors. Handbook of headache. Practical management. Berlin: Springer; 2011. p. 565–78.CrossRef
7.
Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia. 2004;24(Suppl 1):1–160.
8.
Kienbacher C, Wöber C, Zesch H, et al. Clinical features, classification and prognosis of migraine and tension-type headache in children and adolescents: a long-term follow-up study. Cephalalgia. 2006;26(7):820–30.PubMedCrossRef
9.
Arruda MA, Bigal ME. Migraine and migraine subtypes in preadolescent children: association with school performance. Neurology. 2012;79(18):1881–8.PubMedCrossRef
10.
Arruda MA, Bigal ME. Behavioral and emotional symptoms and primary headaches in children: a population-based study. Cephalalgia. 2012;32(15):1093–100.PubMedCrossRef
11.
Kröner-Herwig B, Gassmann J. Headache disorders in children and adolescents: their association with psychological, behavioral, and socio-environmental factors. Headache. 2012;52(9):1387–401.PubMedCrossRef
12.
Karwautz A, Wöber C, Lang T, Böck A, Wagner-Ennsgraber C, Vesely C, et al. Psychosocial factors in children and adolescents with migraine and tension-type headache: a controlled study and review of the literature. Cephalalgia. 1999;19(1):32–43.PubMedCrossRef
13.
Kernick D, Reinhold D, Campbell JL. Impact of headache on young people in a school population. Br J Gen Pract. 2009;59(566):678–81.PubMedCrossRef
14.
Wöber-Bingöl Ç, Hershey A. Migraine co-morbidities in children. In: Schoenen J, Sandor P, Dodick D, editors. Co-morbidity in migraine—clinical aspects, prevalence, mechanisms and management. Chichester: Wiley-Blackwell; 2011. p. 122–32.
15.
Termine C, Özge A, Antonaci F, et al. Overview of diagnosis and management of paediatric headache. Part II: therapeutic management. J Headache Pain. 2011;12(1):25–34.PubMedCrossRef
16.
Abu-Arafeh I, Pearlman E. Childhood migraine and related syndromes. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, editors. The headaches. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 1073–7.
17.
Evers S, Marziniak M, Frese A, et al. Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies. Cephalalgia. 2009;29(4):436–44.PubMedCrossRef
18.
Benedetti F, Mayberg HS, Wager TD, et al. Neurobiological mechanisms of the placebo effect. J Neurosci. 2005;25(45):10390–402.PubMedCrossRef
19.
Hämäläinen ML, Hoppu K, Valkeila E, et al. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997;48(1):102–7.CrossRef
20.
Lewis DW, Kellstein D, Dahl G, et al. Children’s ibuprofen suspension for the acute treatment of pediatric migraine headache. Headache. 2002;42(8):780–6.PubMedCrossRef
21.
Evers S, Rahmann A, Kraemer C, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology. 2006;67(3):497–9.PubMedCrossRef
22.
Southey ER, Soares-Weiser K, Kleijnen J. Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. Curr Med Res Opin. 2009;25(9):2207–22.PubMedCrossRef
23.
Bárzaga Arencibia Z, Choonara I. Balancing the risks and benefits of the use of over-the-counter pain medications in children. Drug Saf. 2012;35(12):1119–25.PubMedCrossRef
24.
Hämäläinen ML, Hoppu K, Santavuori P. Oral dihydroergotamine for therapy-resistant migraine attacks in children. Pediatr Neurol. 1997;16(2):114–7.PubMedCrossRef
25.
Hämäläinen M, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently than adults? Neurology. 1997;48(4):1100–3.PubMedCrossRef
26.
Uebarall MA. Intranasal sumatriptan for the acute treatment of migraine in children. Neurology. 1999;52(7):1507–10.CrossRef
27.
Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000;106(5):989–97.PubMedCrossRef
28.
Winner P, Rothner AD, Wooten JD, et al. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache. 2006;46(2):212–22.PubMedCrossRef
29.
Ahonen K, Hämäläinen ML, Rantala H, et al. Nasal sumatriptan is effective in the treatment of migraine attacks in children. Neurology. 2004;62(6):883–7.PubMedCrossRef
30.
Wöber C, Wöber-Bingöl Ç. Intranasal sumatriptan for the acute treatment of migraine in children. (Letter). Neurology. 2000;54(5):1209–10.PubMedCrossRef
31.
Christensen ML, Mottern RK, Jabbour JT, et al. Pharmacokinetics of sumatriptan nasal spray in children. J Clin Pharmacol. 2004;44(4):359–67.PubMedCrossRef
32.
Christensen ML, Mottern RK, Jabbour JT, et al. Pharmacokinetics of sumatriptan nasal spray in adolescents. J Clin Pharmacol. 2003;43(7):721–6.PubMed
33.
Tfelt-Hansen P, Olesen J. Taking the negative view of current migraine treatments: the unmet needs. CNS Drugs. 2012;26(5):375–82.PubMedCrossRef
34.
Rothner AD, Wasiewski W, Winner P, et al. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache. 2006;46(1):101–9.PubMedCrossRef
35.
Lewis DW, Winner P, Hershey AD, et al. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics. 2007;120(2):390–6.PubMedCrossRef
36.
Dixon R, Engleman K, Kemp J, et al. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults. J Child Adolesc Psychopharmacol. 1999;9(1):35–42.PubMedCrossRef
37.
Winner P, Lewis D, Visser WH, et al. Rizatriptan Adolescent Study Group. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache. 2002;42(1):49–55.PubMedCrossRef
38.
Visser WH, Winner P, Strohmaier K, Rizatriptan Protocol 059 and 061 Study Groups, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache. 2004;44(9):891–9.PubMedCrossRef
39.
Ahonen K, Hämäläinen ML, Eerola M, et al. A randomized trial of rizatriptan in migraine attacks in children. Neurology. 2006;67(7):1135–40.PubMedCrossRef
40.
Ho TW, Pearlman E, Lewis D, et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia. 2012;32(10):750–65.PubMedCrossRef
41.
Hewitt DJ, Pearlman E, Hämäläinen M, et al. Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineurs. Headache. 2013;53(1):104–17.PubMedCrossRef
42.
Fraser IP, Han L, Han TH, et al. Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. Headache. 2012;52(4):625–35.PubMedCrossRef
43.
Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache. 2008;48(9):1326–36.PubMedCrossRef
44.
Berenson F, Vasconcellos E, Pakalnis A, et al. Long-term, open-label safety study of oral almotriptan 12.5 mg for the acute treatment of migraine in adolescents. Headache. 2010;50(5):795–807.PubMedCrossRef
45.
Baldwin JR, Fleishaker JC, Azie NE, et al. A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults. Cephalalgia. 2004;24(4):288–92.PubMedCrossRef
46.
Winner P, Linder SL, Lipton RB, Almas M, Parsons B, Pitman V. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache. 2007;47(4):511–8.PubMedCrossRef
47.
Khoury CK, Couch JR. Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. Drug Des Devel Ther. 2010;4:9–17.PubMedCrossRef
48.
Derosier FJ, Lewis D, Hershey AD, Winner PK, Pearlman E, Rothner AD, Linder SL, Goodman DK, Jimenez TB, Granberry WK, Runken MC. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics. 2012;129(6):e1411–20.PubMedCrossRef
49.
McDonald SA, Hershey AD, Pearlman E, et al. Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents. Headache. 2011;51(9):1374–87.PubMedCrossRef
50.
Walls CM, Berges AC, Dalton ZX, et al. Pharmacokinetics of sumatriptan and naproxen following the administration of a single combination tablet at three doses to adolescent subjects with migraine and healthy adult subjects. Headache. 2010;50(S1):8–9.
51.
Lindkvist J, Airaksinen M, Kaukonen AM, et al. Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994–2007. Br J Clin Pharmacol. 2011;71(6):929–35.PubMedCrossRef
Metadata
Title
Pharmacological Treatment of Acute Migraine in Adolescents and Children
Author
Çiçek Wöber-Bingöl
Publication date
01-06-2013
Publisher
Springer International Publishing AG
Published in
Pediatric Drugs / Issue 3/2013
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-013-0019-3

Other articles of this Issue 3/2013

Pediatric Drugs 3/2013 Go to the issue

Review Article

Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents

Review Article

Medication Discrepancies at Transitions in Pediatrics: A Review of the Literature

Original Research Article

A Predictive Pharmacokinetic/Pharmacodynamic Model of Fentanyl for Analgesia/Sedation in Neonates Based on a Semi-Physiologic Approach

Leading Article

Potential Therapies for Anaplastic Lymphoma Kinase-Driven Tumors in Children: Progress to Date

Review Article

Premenstrual Dysphoric Disorder and Severe Premenstrual Syndrome in Adolescents

Review Article

Difficult-to-Treat Asthma in Childhood